Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840
Debt
Debt-to-Equity RatioN/A
Current Ratio3.58
Quick Ratio3.58
Price-To-Earnings
Trailing P/E Ratio-12.79
Forward P/E Ratio-4.91
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.64 million
Price / Sales3.31
Cash FlowN/A
Price / CashN/A
Book Value$5.18 per share
Price / Book1.40
Profitability
EPS (Most Recent Fiscal Year)($0.57)
Net Income$-16,440,000.00
Net Margins-50.54%
Return on Equity-23.27%
Return on Assets-11.42%
Miscellaneous
Employees112
Outstanding Shares32,630,000
Market Cap$273.09 million
Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions
What is Jounce Therapeutics' stock symbol?
Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics Inc (NASDAQ:JNCE) posted its earnings results on Friday, August, 10th. The company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.37) by $0.23. The company had revenue of $19.38 million for the quarter, compared to analysts' expectations of $12.47 million. Jounce Therapeutics had a negative net margin of 50.54% and a negative return on equity of 23.27%. View Jounce Therapeutics' Earnings History.
When is Jounce Therapeutics' next earnings date?
What price target have analysts set for JNCE?
6 equities research analysts have issued 1 year price targets for Jounce Therapeutics' stock. Their predictions range from $10.00 to $20.00. On average, they anticipate Jounce Therapeutics' share price to reach $13.20 in the next year. This suggests a possible upside of 81.6% from the stock's current price. View Analyst Price Targets for Jounce Therapeutics.
What is the consensus analysts' recommendation for Jounce Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jounce Therapeutics.
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include DBV TECHNOLOGIE/S (DBVT), Autolus Therapeutics (AUTL), Avrobio (AVRO), BAVARIAN NORDIC/S (BVNRY), Adaptimmune Therapeutics (ADAP), BioCryst Pharmaceuticals (BCRX), Heska (HSKA), CASI Pharmaceuticals (CASI), Fate Therapeutics (FATE), La Jolla Pharmaceutical (LJPC), Mesoblast (MESO), Voyager Therapeutics (VYGR), Vericel (VCEL), Novavax (NVAX) and Replimune Group (REPL).
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the folowing people:
- Dr. Richard Murray, Pres, CEO & Director (Age 59)
- Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 53)
- Dr. Elizabeth G. Trehu, Chief Medical Officer (Age 58)
- Dr. James P. Allison, Founder
- Dr. Thomas F. Gajewski, Founder
When did Jounce Therapeutics IPO?
(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
Has Jounce Therapeutics been receiving favorable news coverage?
News headlines about JNCE stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jounce Therapeutics earned a media and rumor sentiment score of 0.11 on Accern's scale. They also assigned news articles about the company an impact score of 45.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Jounce Therapeutics.
Who are Jounce Therapeutics' major shareholders?
Jounce Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (9.06%), BlackRock Inc. (4.29%), Redmile Group LLC (3.72%), Millennium Management LLC (2.08%), Dimensional Fund Advisors LP (0.97%) and Spark Investment Management LLC (0.66%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.
Which institutional investors are selling Jounce Therapeutics stock?
JNCE stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, FMR LLC, Tocqueville Asset Management L.P., Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.
Which institutional investors are buying Jounce Therapeutics stock?
JNCE stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, Spark Investment Management LLC, Alambic Investment Management L.P., Connor Clark & Lunn Investment Management Ltd., Redmile Group LLC and Bank of America Corp DE. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc, Hugh M Cole and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.
How do I buy shares of Jounce Therapeutics?
Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jounce Therapeutics' stock price today?
One share of JNCE stock can currently be purchased for approximately $7.27.
How big of a company is Jounce Therapeutics?
Jounce Therapeutics has a market capitalization of $273.09 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.
How can I contact Jounce Therapeutics?
Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.
MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
